focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Notification of Major Interest in Shares

3 Aug 2012 17:35

For filings with the FSA include the annex For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer SILENCE THERAPEUTICSof existing shares to which voting rights are

PLCattached:ii

2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result

in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to Xqualifying financial instruments An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the

ROBERT KEITHnotification obligation:iii 4. Full name of shareholder(s) Rock ( Nominees) Limited (if different from 3.):iv

5. Date of the transaction and date on which the threshold is crossed or

02.08.12reached: v

6. Date on which issuer notified:

03.08.12

7. Threshold(s) that is/are crossed or

18%reached: vi, vii 8. Notified details:

A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering transaction of to the triggering shares transaction Number Number Number Number of voting % of voting rights x if possible of of of shares rights using Shares Voting the ISIN Rights Direct Direct xi Indirect Direct Indirect CODE xii GB0008433350 54,089,628 3.68% 254,089,628 254,089,628 17.33%

B: Qualifying Financial Instruments Resulting situation after the triggering transaction

Type of Expiration Exercise/ Number of voting % of voting financial date xiii Conversion Period xiv rights that may be rights instrument acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting rights % of voting rights financial date xvii Conversion instrument refers to xix, xx instrument period xviii Nominal Delta Spreadbet n/a n/a n/a 14,236,216 0.97% 0.97% Total (A+B+C) Number of voting rights Percentage of voting rights 268,325,844 18.30%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Proxy Voting: 10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease

to hold:

12. Date on which proxy holder will cease to hold

voting rights: 13. Additional information: 14. Contact name: ROBERT KEITH

15. Contact telephone number:

0207 491 0581

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii

A: Identity of the persons or legal entity subject to the notification

obligation Full name

(including legal form of legal entities)

Contact address

(registered office for legal entities)

Phone number & email Other useful information

(at least legal representative for legal persons)

B: Identity of the notifier, if applicable

Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
16th Jan 20132:16 pmRNSHolding(s) in Company
14th Jan 20133:08 pmRNSReplacement - Exercise of warrants
14th Jan 20137:00 amRNSExercise of warrants
2nd Jan 20138:36 amRNSAppointment of Chief Medical Officer
31st Dec 201210:30 amRNSHolding(s) in Company
28th Dec 20127:00 amRNSTotal Voting Rights
6th Dec 20124:22 pmRNSHolding(s) in Company
3rd Dec 20123:12 pmRNSOption exercise
3rd Dec 20121:36 pmRNSHolding(s) in Company
3rd Dec 20121:34 pmRNSHolding(s) in Company
30th Nov 201212:52 pmRNSHolding(s) in Company
30th Nov 20128:05 amRNSHolding(s) in Company
30th Nov 20127:00 amRNSOption Exercise and TVR
28th Nov 20128:33 amRNSDirector/PDMR Shareholding
28th Nov 20127:49 amRNSSubscription and Conversion
21st Nov 20127:00 amRNSProposed Placing
5th Nov 201212:52 pmRNSAdviser Change of Name
5th Nov 201210:24 amPRNUS allows two key patents for Silence Therapeutics
19th Oct 20127:00 amPRNExercise of warrants
15th Oct 20127:01 amPRNExercise of warrants
15th Oct 20127:00 amPRNAppointment of finance director
25th Sep 20127:00 amPRNInterim Results for the Six Months Ended 30 June 2012
20th Sep 20122:59 pmPRNNotice of Results
18th Sep 20127:00 amPRNAppointment of Chief Medical Adviser
10th Sep 201211:12 amPRNTR-1: Notification of Major Interest in Shares
10th Sep 20127:00 amPRNSignificant Pre-clinical Data in Acute Lung Injury
4th Sep 201212:19 pmPRNTR-1: Notification of Major Interest in Shares
29th Aug 20124:40 pmRNSSecond Price Monitoring Extn
29th Aug 20124:35 pmRNSPrice Monitoring Extension
24th Aug 20122:41 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
22nd Aug 20127:00 amPRNCollaboration with MiReven Pty Ltd
20th Aug 20122:44 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
10th Aug 201212:20 pmPRNHolding(s) in Company
6th Aug 201212:21 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
3rd Aug 20125:35 pmPRNTR-1: Notification of Major Interest in Shares
2nd Aug 201212:12 pmPRNTR-1: Notification of Major Interest in Shares
2nd Aug 20129:00 amPRNAdmission of shares and Board update
31st Jul 201211:26 amPRNNotice of EGM
31st Jul 20127:00 amPRNResults of Open Offer
30th Jul 20125:35 pmPRNHolding(s) in Company
27th Jul 201212:12 pmPRNTR-1: Notification of Major Interest in Shares
24th Jul 20124:35 pmRNSPrice Monitoring Extension
13th Jul 20122:48 pmPRNReplacement - Subscription and Open Offer
12th Jul 20127:00 amPRNSubscription and Open Offer to Raise up to £5.7 million
10th Jul 201210:34 amPRNResponse to press speculation
22nd Jun 20121:35 pmPRNResult of Annual General Meeting
6th Jun 201212:00 pmPRNPhase I data for Atu027 and Potential Fundraising
17th May 20127:00 amPRNNew data from Phase I trial with Atu027
14th May 20127:00 amPRNPublication of 2011 Annual Report and Notice of AGM
3rd May 20127:00 amPRNSilence Therapeutics’ Partner extends agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.